Whereas over 5 million endovascular procedures are carried out within the U.S. every year, Microbot says lower than 1% are achieved robotically. | Supply: Microbot Medical
Microbot Medical right now introduced its Liberty endovascular surgical robotic earned 510(ok) clearance from the U.S. Meals and Drug Administration (FDA). The corporate claimed this makes Liberty the primary FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
“Acquiring FDA 510(ok) clearance for Liberty marks a defining second for Microbot Medical and, we consider, for the way forward for endovascular robotics. This achievement validates our mission to develop entry to superior robotic applied sciences whereas addressing crucial unmet wants and supporting cost-effective healthcare,” Harel Gadot, chairman, CEO, and president of Microbot Medical, mentioned.
“With our industrial readiness technique being developed and executed since Q2 this yr, we consider we’re well-positioned to speed up market entry. With FDA clearance, we will now full the ultimate industrial actions that have been contingent on advertising clearance, positioning us to begin commercialization, penetrate the roughly 2.5 million annual U.S. peripheral vascular procedures, and pursue entry into international markets,” he continued.
The FDA clearance positions the corporate to commercialize Liberty within the U.S. The Liberty pivotal examine confirmed 100% success within the robotic navigation to focus on, and nil device-related hostile occasions, Microbot mentioned. The examine additionally confirmed a 92% relative discount in radiation publicity for physicians.
Microbot plans for wider purposes sooner or later
Microbot mentioned Liberty is an endovascular robotic system for interventional physicians and hospitals in search of to enhance procedural precision, security, and effectivity. In contrast to conventional handbook strategies, Liberty gives a single-use, compact answer that permits managed distant operation.
The surgical robotic can be utilized in neurovascular, cardiovascular, and peripheral vascular procedures. The system features a compact design and distant working capabilities. Microbot additionally claimed that Liberty has the potential to decrease process prices, improve process effectivity, and enhance the general high quality of care.
In August, Microbot introduced a brand new patent protecting a modular robotic surgical system. The system features a base and a plurality of tool-receiver items organized as separate items. These items are independently and interchangeably attachable to the bottom. The corporate mentioned the patent will probably allow it to adapt Liberty sooner or later for a wider vary of endovascular procedures.
With the most recent patent, Microbot now has 12 patents globally and 57 patent purposes pending. Microbot Medical is a pre-commercial-stage medical know-how supplier. It mentioned its imaginative and prescient is to enhance the standard of take care of tens of millions of sufferers and suppliers globally. The Braintree, Mass.-based firm mentioned Liberty is step one towards its aim of rethinking how robotics can profit healthcare.
Surgical robotics will on the agenda at RoboBusiness, which takes place Oct. 15-16 in Santa Clara, Calif. Iman Jeddi, Ph.D., senior vice chairman and normal supervisor of Intuitive’s multiport platform, will supply a uncommon look contained in the redesign and launch of the da Vinci 5, the firm‘s next-generation surgical robotics system.
